Evidence map›Paper›PMID 30361923›Full record

ArticleLa Radiologia medica2019

Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey.

Giorgia Timon, Barbara Alicja Jereczek-Fossa, Sergio Fersino, Cinzia Iotti, Renzo Corvò, Stefano Maria Magrini, Filippo Alongi

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Giorgia TimonRadioterapia Oncologica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy. giorgiatimon@gmail.com.ORCID http://orcid.org/0000-0002-1555-0940
Barbara Alicja Jereczek-FossaDivisione di Radioterapia, IEO Istituto Europeo di Oncologia IRCCS, Milan, Italy.
Sergio FersinoRadioterapia Oncologica, Ospedale Santa Chiara di Trento, Trento, Italy.
Cinzia IottiRadioterapia Oncologica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Renzo CorvòDipartimento di Radioterapia Oncologica, IRCCS Policlinico San Martino e Università degli Studi di Genova, Genoa, Italy.
Stefano Maria MagriniDipartimento di Radioterapia Oncologica, Università e Spedali Civili di Brescia, Brescia, Italy.
Filippo AlongiUOC Radioterapia Oncologica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy.
Azienda Sanitaria Unità Locale di Reggio Emilia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITOspedale Policlinico San Martino · ITOspedale Sacro Cuore Don Calabria · ITOspedale Santa Chiara · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe purpose of this survey was to investigate the current opinion among Italian radiation oncologists regarding the non-palliative radiotherapy in ab initio oligometastatic prostate cancer (OMPC) patients.

methodsA link to complete the survey was sent via e-mail to Italian radiation oncologists on February 2018. It was requested that only one physician per facility completed the survey, and that he/she was dedicated to PC management in his/her daily clinical practice. The questionnaire consisted of 15 questions concerning the management of OMPC.

resultsOne hundred and eleven radiation oncologists filled in the questionnaire. The majority of them see ≤ 10 patients affected by OMPC in a year. More than 80% of respondents would perform radiotherapy (RT) to both the prostate and all metastases sites, but mostly up to 2-3 metastases; furthermore, > 80% of physicians would perform RT on both nodal and bone secondary lesions. Most respondents deem a choline- or prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) mandatory before considering a patient affected by OMPC for non-palliative RT. The association of RT with androgen deprivation therapy for at least 12 months would be recommended by > 50% of respondents. In the follow-up phase, the majority would suggest a clinical examination and PSA every 3-6 months and a choline- or PSMA-PET only at biochemical progression. More than 90% of respondents confirmed to be interested in participating in a multicentre study regarding this subject.

conclusionsThis survey investigated the current opinion of Italian radiation oncologists and confirmed their interest in OMPC management.

Indexed as

Health Care SurveysPractice Patterns, Physicians'Radiation OncologyHumansItalyMaleNeoplasm MetastasisProstatic NeoplasmsOligometastaticProstate cancerRadiotherapySurvey

Identifiers

PMID30361923
OpenAlexW2898460081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.